Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Minister Komiyama to Focus on Social Security Reform
September 5, 2011
- Noda Cabinet: MHLW Vice Minister Komiyama Promoted to Minister
September 5, 2011
- New EAD Director Kamata Supports Making Premium for New Drug Development Permanent
September 5, 2011
- METI to Establish New Company to Support Medical Tourism from Overseas
September 5, 2011
- Avastin Recommended for Approval for Breast Cancer
September 5, 2011
- Fingolimod Recommended for Approval
September 5, 2011
- Make the Premium for New Drug Development Permanent: FPMAJ, PhRMA, EFPIA Japan
September 5, 2011
- Increases in Social Security Spending to Be Covered by Cuts in Other Spending: FY2012 Budget
September 5, 2011
- US FDA Approves Vemurafenib for Melanoma; to Be Copromoted by Daiichi Sankyo
September 5, 2011
- Patent Office to Revise GL for Application of Patent Extension System
September 5, 2011
- Korosho to Apply for PIC/S Membership in Early FY2012: New CND Director Nakaigawa
September 5, 2011
- Almarl or Amaryl Should Be Renamed to Prevent Mistakes: MHLW
September 1, 2011
- Anticancer Drug Dispensed Instead of Norvasc Generic: MHLW Report
September 1, 2011
- Upgrading Quality Both in Facilities, Research for ICH-GCP: RDD Director Sahara
September 1, 2011
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…